Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  05-23
808000.00 KRW   -1.34%
05/23SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies; SK Hynix Loses 2%
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics' Q4 Net Profit Slumps, Revenue Jumps

01/25/2022 | 05:42am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
KOSPI COMPOSITE INDEX -1.26% 2610.67 Real-time Quote.-12.29%
SAMSUNG BIOLOGICS CO.,LTD. -1.34% 808000 End-of-day quote.-10.52%
SAMSUNG ELECTRONICS CO., LTD. -2.06% 66500 End-of-day quote.-15.07%
All news about SAMSUNG BIOLOGICS CO.,LTD.
05/23SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,58 B 1,58 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,45 B 0,45 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 509 B 45 499 M 45 499 M
EV / Sales 2022 29,2x
EV / Sales 2023 25,6x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 808 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.52%46 268
CSL LIMITED-6.04%93 536
WUXI BIOLOGICS (CAYMAN) INC.-39.22%30 229
BIOGEN INC.-16.89%29 203
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%22 798
UCB-17.29%16 779